Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.

# Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.  **Read the full article:** [CNBC](https://www.cnbc.com/2026/10/24/amgen-imdelltra-lung-cancer-data.html) *This article was originally published by CNBC. MoneyWiseInc provides expert curation of the best financial content from trusted sources.*